Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
View original at finance.yahoo.comRigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Median PFS was 5.0 months in the vepdegestrant arm and 2.1 months in the fulvestrant arm in VERITAC-2.
60% confidenceOverall survival data was immature at the time of the PFS analysis, with 16% of deaths recorded in the population.
60% confidenceThe licensing agreement allows Rigel to launch VEPPANU in the U.S. and pursue global rights, potentially leading to significant revenue growth.
60% confidenceRigel will contribute up to $40 million towards VEPPANU development over the next four years under the licensing agreement.
60% confidenceThe FDA approval of vepdegestrant was based on data showing the drug reduced the risk of disease progression or death by 43% compared to fulvestrant.
60% confidenceIn the Phase 3 VERITAC-2 trial, vepdegestrant was generally well tolerated and demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant.
60% confidence